Abstract
A single dose of TS-110 at 4, 6, and 8mg was administered to patients suffering from postextraction pain of the lower mandibular impacted wisdom tooth.
Early investigation of the drug's clinical usefulness and estimation of optimum dosage were made.
1. For assessment of overall improvement of pain and analysis of usefulness, there were 39, 37, and 31 cases in the 4, 6, and 8mg groups respectively. For analysis of overall safety, there were 39, 37, and 32 cases in respective groups.
2. The ratio of cases which showed moderate improvement of pain or better was 74.4%, 86.5%, and 80.6% in the 4, 6, and 8mg groups respectively.
3. Administration of TS-110 caused no adverse reactions.
4. The ratio of cases which showed useful or greater was 66.7%, 81.1%, and 87.1% in the 4, 6, and 8mg groups respectively.
These results suggest that TS-110 produces significant dose-dependent improvement of postextraction pain and that there is no problem concerning safety.
